Laura Sangaré
Research Subjects
Research Interests
Laura Sangaré has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Kimberly A. Lowe
Amgen Inc., Seattle, WA
2 shared publications Akhila Balasubramanian
Amgen Inc., Thousand Oaks, CA, USA
1 shared publication- Alecia Divita
Adelphi Research, Doylestown, USA
1 shared publication - Ana Florea
Kaiser Permanente Southern California
1 shared publication D Gwyn Bebb
University of Calgary, Calgary, Alberta, Canada
1 shared publicationDeborah Nichols
Purdue University, West Lafayette, US
1 shared publication
Latest Publications
- Open Access
- 12 August 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-7
The risk of sleep-related death in an inclined sleep environment
Background: Unsafe sleep environments are the primary modifiable risk factor for sudden unexpected infant death (SUID). Despite this knowledge, products that deviate from the American Academy of Pediatrics (AAP) safe sleep recommendations continue to be commonplace, such as inclined sleepers. Analyses to estimate risk among these products are lacking, perpetuating their presence in the marketplace. We present a method of comparing risk of SUID in an inclined sleeper to an AAP-recommended sleep environment. Methods: A case-control analysis using publicly available and previously published survey data was conducted for SUID events occurring between January 1, 2018 and April 12, 2019 (the date of the first inclined sleeper recall). SUID deaths were categorized as occurring in an AAP-recommended sleep environments or in an inclined sleeper. Exposure Odds Ratios (OR) are reported as the risk of SUID among infants using inclined sleepers relative to an AAP-recommended sleep environment. Results: During the study period, 4,900,573 births and 4,363 SUID deaths occurred in the US. Control characteristics were similar between previous night users of an AAP-recommended sleep environment (24%) and inclined sleepers (3.8%). Inclined sleepers were associated with a 5-fold (OR: 5.1; 95% CI: 3.2, 7.9) increased risk of SUID among infants < 12 months compared to infants in an AAP-recommended sleep environment. This risk was greatest among infants ≥ 4 months (RR: 10.4; 95% CI: 5.1, 21.5). Conclusions: This novel analysis fills a longstanding gap in risk assessments of inclined infant sleep products. More timely risk analyses may improve the safety of the marketplace.
- 12 August 2024
- Published by Springer Nature in BMC Public Health
- Vol. 24 (1) , 1-7
Open AccessThe risk of sleep-related death in an inclined sleep environment
Background: Unsafe sleep environments are the primary modifiable risk factor for sudden unexpected infant death (SUID). Despite this knowledge, products that deviate from the American Academy of Pediatrics (AAP) safe sleep recommendations continue to be commonplace, such as inclined sleepers. Analyses to estimate risk among these products are lacking, perpetuating their presence in the marketplace. We present a method of comparing risk of SUID in an inclined sleeper to an AAP-recommended sleep environment. Methods: A case-control analysis using publicly available and previously published survey data was conducted for SUID events occurring between January 1, 2018 and April 12, 2019 (the date of the first inclined sleeper recall). SUID deaths were categorized as occurring in an AAP-recommended sleep environments or in an inclined sleeper. Exposure Odds Ratios (OR) are reported as the risk of SUID among infants using inclined sleepers relative to an AAP-recommended sleep environment. Results: During the study period, 4,900,573 births and 4,363 SUID deaths occurred in the US. Control characteristics were similar between previous night users of an AAP-recommended sleep environment (24%) and inclined sleepers (3.8%). Inclined sleepers were associated with a 5-fold (OR: 5.1; 95% CI: 3.2, 7.9) increased risk of SUID among infants < 12 months compared to infants in an AAP-recommended sleep environment. This risk was greatest among infants ≥ 4 months (RR: 10.4; 95% CI: 5.1, 21.5). Conclusions: This novel analysis fills a longstanding gap in risk assessments of inclined infant sleep products. More timely risk analyses may improve the safety of the marketplace.
- Open Access
- 9 May 2024
- Published by Elsevier in Lung Cancer
- Vol. 193, 107819
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world study
- 9 May 2024
- Published by Elsevier in Lung Cancer
- Vol. 193, 107819
Open AccessNatural history of SCLC patients treated in third-line and beyond: A retrospective real world study
- Open Access
- 11 May 2021
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (11) , 6731-6740
Navigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix
Purpose: To understand the extent to which metastatic colorectal cancer (mCRC) patients receive education on the prevention and management associated with skin rash following Vectibix treatment. Furthermore, to investigate how this adverse event affects a patient’s quality of life (QoL) and influences their treatment decisions. Methods: A cross-sectional survey was administered to 200 mCRC patients (100 Vectibix users and 100 Vectibix non-users). After excluding respondents who had used cetuximab, 61 Vectibix users and 56 Vectibix non-users remained. Results: Most Vectibix users (79%) experienced a skin rash in response to treatment of which 65% considered the rash moderate, 27% mild, and 8% severe. Vectibix users generally felt they were adequately informed about the rash (83%), with the most common messages received related to sun protection. However, sunscreen was used by only 42% of patients prior to rash and 60% of patients following the appearance of rash. The use of oral antibiotics was low prior to rash (21%) and following rash (46%). Among patients experiencing a rash within the past week (n=16), 75% reported the rash had a large negative impact on their QoL based on the Dermatology Life Quality Index. Conclusion: There was a disconnect between patients feeling they were adequately informed and use of prevention and management strategies such as sun protection. This suggests a gap in patient education and adoption currently exists on management strategies both prior to and following the appearance of rash. Given the negative impact that skin toxicity has on the patient’s quality of life, it is essential that patients receive and subsequently utilize all information that can minimize rash severity.
- 11 May 2021
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (11) , 6731-6740
Open AccessNavigating metastatic colorectal treatment options in the USA: a survey of patient acceptance of skin toxicities associated with Vectibix
Purpose: To understand the extent to which metastatic colorectal cancer (mCRC) patients receive education on the prevention and management associated with skin rash following Vectibix treatment. Furthermore, to investigate how this adverse event affects a patient’s quality of life (QoL) and influences their treatment decisions. Methods: A cross-sectional survey was administered to 200 mCRC patients (100 Vectibix users and 100 Vectibix non-users). After excluding respondents who had used cetuximab, 61 Vectibix users and 56 Vectibix non-users remained. Results: Most Vectibix users (79%) experienced a skin rash in response to treatment of which 65% considered the rash moderate, 27% mild, and 8% severe. Vectibix users generally felt they were adequately informed about the rash (83%), with the most common messages received related to sun protection. However, sunscreen was used by only 42% of patients prior to rash and 60% of patients following the appearance of rash. The use of oral antibiotics was low prior to rash (21%) and following rash (46%). Among patients experiencing a rash within the past week (n=16), 75% reported the rash had a large negative impact on their QoL based on the Dermatology Life Quality Index. Conclusion: There was a disconnect between patients feeling they were adequately informed and use of prevention and management strategies such as sun protection. This suggests a gap in patient education and adoption currently exists on management strategies both prior to and following the appearance of rash. Given the negative impact that skin toxicity has on the patient’s quality of life, it is essential that patients receive and subsequently utilize all information that can minimize rash severity.
- 29 November 2019
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 51 (3) , 965-971
A Multinational Assessment of Gastric, Esophageal, and Colorectal Cancer Burden: A Report of Disease Incidence, Prevalence, and Fatality
Introduction Digestive cancers, including colorectal, stomach, and esophageal cancer, represent one-third of all new cancer cases in the world. This comprehensive analysis seeks to summarize the burden of digestive system cancers on a global scale, within specific countries in the Americas, Europe, Asia, Oceania, and Africa. Methods Burden is measured using prevalence, incidence, and case-fatality rates. Estimates of incidence rates and case-fatality ratios were further stratified by gender and age group (< 65 years and ≥ 65 years). Results In general, these data highlight differences in the prevalence and incidence of gastric, esophageal, and colorectal cancers by gender and region. Large variations in case-fatality rates by gender and age are also present. Conclusions These data illustrate the worldwide burden of digestive diseases and may help guide resource allocation to decrease the impact of digestive cancers around the world.
- 29 November 2019
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 51 (3) , 965-971
A Multinational Assessment of Gastric, Esophageal, and Colorectal Cancer Burden: A Report of Disease Incidence, Prevalence, and Fatality
Introduction Digestive cancers, including colorectal, stomach, and esophageal cancer, represent one-third of all new cancer cases in the world. This comprehensive analysis seeks to summarize the burden of digestive system cancers on a global scale, within specific countries in the Americas, Europe, Asia, Oceania, and Africa. Methods Burden is measured using prevalence, incidence, and case-fatality rates. Estimates of incidence rates and case-fatality ratios were further stratified by gender and age group (< 65 years and ≥ 65 years). Results In general, these data highlight differences in the prevalence and incidence of gastric, esophageal, and colorectal cancers by gender and region. Large variations in case-fatality rates by gender and age are also present. Conclusions These data illustrate the worldwide burden of digestive diseases and may help guide resource allocation to decrease the impact of digestive cancers around the world.